NCT07177885 Tryptophan as a Modulating Factor in the Antimigraine Efficacy of Triptans
| NCT ID | NCT07177885 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Clermont-Ferrand |
| Condition | Migraine |
| Study Type | OBSERVATIONAL |
| Enrollment | 144 participants |
| Start Date | 2026-03-05 |
| Primary Completion | 2028-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 144 participants in total. It began in 2026-03-05 with a primary completion date of 2028-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Migraine is a leading cause of disability, and while triptans are commonly used to treat migraine attacks, over 20% of patients don't respond well to them. This study aims to understand why some people don't benefit from triptans. One key focus is tryptophan, an amino acid that plays a role in migraine and is involved in producing serotonin, which affects pain and inflammation. The study will compare levels of tryptophan and its by-products in patients who respond well to triptans versus those who don't. It will also look at how conditions like inflammatory bowel disease may affect tryptophan absorption. The goal is to improve migraine treatments tailored to different patient needs, though participants may not experience immediate personal benefits.
Eligibility Criteria
Inclusion Criteria: * Cisgender women, premenopausal, aged 18 to 50 years. * Cisgender men, aged 18 to 50 years. * Diagnosed with migraine (according to ICHD-3 criteria). * Diagnosed as responders or non-responders to triptans (according to the criteria of Sacco et al., 2022). * Permitted comparison groups include: triptans used alone or in combination with other migraine treatments (e.g., NSAIDs, acetaminophen, ergotamine, opioids, antiemetics). * All routes of administration and all dosages. * Affiliation with a social security system. Exclusion Criteria: * Patients under guardianship, curatorship, deprivation of liberty, or legal protection * Pregnant and breastfeeding women
Contact & Investigator
Xavier Moisset
PRINCIPAL INVESTIGATOR
University Hospital, Clermont-Ferrand
Frequently Asked Questions
Who can join the NCT07177885 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07177885 currently recruiting?
Yes, NCT07177885 is actively recruiting participants. Contact the research team at promo_interne_drci@chu-clermontferrand.fr for enrollment information.
Where is the NCT07177885 trial being conducted?
This trial is being conducted at Clermont-Ferrand, France.
Who is sponsoring the NCT07177885 clinical trial?
NCT07177885 is sponsored by University Hospital, Clermont-Ferrand. The principal investigator is Xavier Moisset at University Hospital, Clermont-Ferrand. The trial plans to enroll 144 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.